Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

Summary

Decoy Therapeutics announced it is entering a catalytic phase with momentum in its antiviral pipeline development using its AI-powered D-MAV discovery platform. The company will participate in a Virtual Investor Closing Bell event on April 9, 2026 at 4:00 PM ET to discuss its clinical development path forward.